Venetoclax
Spécifications
1257044-40-8Numéro CAS
820-130-9Numéro CE
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamideNom IUPAC
C45H50ClN7O7SFormule chimique
868.4 g/molMasse molaire
Venetoclax; 1257044-40-8; ABT-199; Venclexta; GDC-0199; ABT199; venclyxto; ABT 199; RG7601; GDC 0199; RG-7601; 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; N54AIC43PW; Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-; CHEBI:133021; DTXSID30154863; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; venetoclaxum; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((oxan-4-yl)methyl)amino)benzenesulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(oxan-4-ylmethylamino)phenyl)sulfonyl-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; 4-(4-((4'-chloro-5,5-dimethyl(3,4,5,6-tetrahydro(1,1'-biphenyl))-2-yl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((oxan-4-yl)methyl)amino)benzene-1-sulfonyl)-2-((1H-pyrrolo(2,3-b)pyridin-5-yl)oxy)benzamide; RefChem:58112; DTXCID0077354; L01XX52; ABT-0199; Venetoclax (ABT-199); Venetoclax (ABT199); UNII-N54AIC43PW; C45H50ClN7O7S; MFCD23160052; Venetoclax; Abt-199; ABT 199 (Venetoclax); 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide; ABT-199 (GDC-0199); 2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide; 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy; BDBM189459; ABT 199 (>99%)(Venetoclax); 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(tetrahydropyran-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; Venetoclax [USAN:INN]; Venclexta (TN); ABBVIE; Venetoclax (Standard); VENETOCLAX [MI]; Venetoclax(ABT-199); VENETOCLAX [INN]; VENETOCLAX [JAN]; VENETOCLAX [USAN]; Venetoclax(ABT-199)?; VENETOCLAX [WHO-DD]; MLS006010298; SCHEMBL523816; Venetoclax (JAN/USAN/INN); GTPL8318; orb1226663; orb1306442; orb3141366; CHEMBL3137309; SCHEMBL19236295; SCHEMBL29353714; SCHEMBL29360081; SCHEMBL29390802; SCHEMBL29801595; VENETOCLAX [ORANGE BOOK]; BDBM60828; EX-A168; GLXC-06797; HMS3653J06; HMS3745E07; HMS5086M05; BDBM50162774; EBC-17182; HY-15531R; NSC766270; AKOS025289539; CCG-270543; CS-1155; DB11581; FV63222; KS-1470; NSC-766270; SB16499; NCGC00345789-01; NCGC00345789-03; NCGC00345789-04; NCGC00345789-05; NCGC00345789-10; NCGC00345789-11; NCGC00345789-12; 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide; AC-28754; BP-43649; DA-35360; HY-15531; SMR004701366; SY048011; CHRONIC LYMPHOCYTIC LEUKAEMIA THERAPY; NS00073446; SW219672-1; T2119; D10679; US9174982, 5; EN300-7399830; US9174982, 369; BRD-K62391742-001-03-0; BRD-K62391742-001-08-9; BRD-K62391742-001-09-7; Q23671272; Z2037279542; )methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; 2-[[Pyrrolo[2,3-b]pyridin-5-yl]oxy]-4-[4-[[4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-2-biphenylyl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(4-tetrahydropyranyl)methyl]amino]phenyl]sulfonyl]benzamide; 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2HPYRAN-4-YLMETHYL) AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide; 4-{4-[(4'-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro[1,1'-biphenyl]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl; 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide; ABT-199; 2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy; VENETOCLAXVENCLEXTAABT-199A-12314-[4-[[2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL]METHYL]PIPERAZIN-1-YL]-N-[[3-NITRO-4-[[(TETRAHYDRO-2H-PYRAN-4-YL)METHYL]AMINO]PHENYL]SULFONYL]-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5-YL)OXY]BENZAMIDESynonymes
Produits contenant Venetoclax
벤클렉스타정50밀리그램(베네토클락스)벤클렉스타정10밀리그램(베네토클락스)벤클렉스타정100밀리그램(베네토클락스)VENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 50 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAVENCLYXTO 50 mg, comprimé pelliculéVENCLYXTO 100 mg, comprimé pelliculéVENCLYXTO 10 mg, comprimé pelliculéVenetoclax - Changzhou Pharmaceutical Factory
Page 1 sur 4
Entreprises vendant Venetoclax
MP
Macleods Pharmaceuticals LimitedIndiaAD
Abbvie Deutschland GmbH & Co. KGGermanyDR
Dr. Reddy's LaboratoriesIndiaML
MSN LaboratoriesIndiaSI
Sinoway Industrial Co.Ltd.ChinaPage 1 sur 3